Feng Jinhui, Zhang Rujin, Zhang Zhengbin, Wu Qiaqing, Zhu Dunming
Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.
National Technology Innovation Center of Synthetic Biology, Tianjin 300308, China.
Sheng Wu Gong Cheng Xue Bao. 2022 Nov 25;38(11):4335-4342. doi: 10.13345/j.cjb.220592.
Steroidal hormone pharmaceuticals are the second largest class of medicines after antibiotics. At present, the initial materials of the steroidal industry have shifted from sapogenins, which were extracted from plants of the genus Dioscore to phytosterols. As a byproduct of soybean oil production, phytosterols are readily available and of low prices. Androstenedione (AD), androstadiendione (ADD), 9α-hydroxy-androstenedione (9α-OH-AD) and a series of key intermediates used in the synthesis of steroidal pharmaceuticals can be produced from phytosterols by microbial transformation. Nevertheless, due to the long metabolic pathways, the byproducts and the complex regulation, traditional microbial screening, mutagenizing methods and the oil-water biphasic transformation systems are no longer suitable for current industrial production. A new generation strains for the production of key steroidal pharmaceutical intermediates have been constructed and an intelligent production process has been jointly developed by us and Zhejiang Xianju Junye Pharmaceutical Co. Ltd.. Taking these products and processes as an example, this article reviews the improvement of strains for the production of steroidal pharmaceutical intermediates and the development of biotransformation process on an industrial scale. With the development of synthetic biology, it is expected to develop a new generation of intermediates which are more suitable for the synthesis of steroidal medicines. Moreover, biosynthesis the steroidal active pharmaceutical ingredients from glucose is also expected. The application of these new-generation strains constructed by biotechnology (BT) in modern factories based on informatization and intelligent technology (IT) will be more efficient and greener, and create remarkable social and economic values.
甾体激素药物是仅次于抗生素的第二大类药物。目前,甾体产业的起始原料已从薯蓣属植物中提取的皂素转变为植物甾醇。作为大豆油生产的副产品,植物甾醇容易获得且价格低廉。雄烯二酮(AD)、雄二烯二酮(ADD)、9α-羟基雄烯二酮(9α-OH-AD)以及一系列用于合成甾体药物的关键中间体都可以通过微生物转化从植物甾醇中生产出来。然而,由于代谢途径长、副产物多以及调控复杂,传统的微生物筛选、诱变方法以及油水双相转化系统已不再适用于当前的工业生产。我们与浙江仙居君业药业有限公司共同构建了用于生产关键甾体药物中间体的新一代菌株,并联合开发了智能生产工艺。以这些产品和工艺为例,本文综述了用于生产甾体药物中间体的菌株改良以及工业规模生物转化工艺的发展。随着合成生物学的发展,有望开发出更适合合成甾体药物的新一代中间体。此外,从葡萄糖生物合成甾体活性药物成分也值得期待。生物技术(BT)构建的这些新一代菌株在基于信息化和智能技术(IT)的现代化工厂中的应用将更加高效和绿色,并创造显著的社会和经济价值。